Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Spondyloarthritis

Treat-to-target in spondyloarthritis—do we have a plan?

Nature Reviews Rheumatology volume 9, pages 507–508 (2013)Cite this article

Subjects

Clinicians now have the therapies and outcome tools to implement treat-to-target strategies aimed at achieving and maintaining adequate function and control of symptoms in spondyloarthritis and psoriatic arthritis. However, validation of surrogate markers of structural progression is a prerequisite for treat-to-target strategies aimed at improving long-term outcomes such as joint damage.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A proposed roadmap for treat-to-target in SpA.2

References

  1. Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631–637 (2010).

    Article  Google Scholar 

  2. Smolen, J. S. et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203419.

  3. Schoels, M. M. et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203860.

  4. van der Heijde, D. M. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis. Res. Ther. 11, R127 (2009).

    Article  Google Scholar 

  5. Gong, Y. et al. Ten years experience on needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum. 64, 1399–1406 (2012).

    Article  Google Scholar 

  6. Lambert, R. G. W. et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis. Arthritis Rheum. 56, 4005–4014 (2007).

    Article  CAS  Google Scholar 

  7. Kiltz, U. et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res. 64, 1415–1422 (2012).

    Article  Google Scholar 

  8. Maksymowych, W. P. et al. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann. Rheum. Dis. 72, 23–28 (2013).

    Article  Google Scholar 

  9. Maksymowych, W. P. et al. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J. Rheumatol. 36, 1792–1799 (2009).

    Article  Google Scholar 

  10. Urata, Y. et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann. Rheum. Dis. 71, 534–540 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, 562 HMRB, University of Alberta, Edmonton, T6G 2S2, AB, Canada

    Walter P. Maksymowych

Authors
  1. Walter P. Maksymowych
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

W. P. Maksymowych declares that he has received honoraria and/or research grants from Abbvie, Amgen, Eli-Lilly, Janssen, Merck, Pfizer, Synarc and UCB, and that he is Chief Medical Officer of Canadian Research and Education (CaRE) Arthritis Limited.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maksymowych, W. Treat-to-target in spondyloarthritis—do we have a plan?. Nat Rev Rheumatol 9, 507–508 (2013). https://doi.org/10.1038/nrrheum.2013.123

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.123

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing